Development of (E)-2-((1,4-Dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-Amidinophenylbenzamides as Potent Inhibitors of Venezuelan Equine Encephalitis Virus

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8608-8621

  Schroeder, Chad E ^a   Yao, Tuanli ^a   Sotsky, Julie ^b   Smith, Robert A ^a   Roy, Sudeshna ^a   Chu, Yong Kyu ^b   Guo, Haixun ^b   Tower, Nichole A ^c   Noah, James W ^c   McKellip, Sara ^c   Sosa, Melinda ^c   Rasmussen, Lynn ^c   Smith, Layton H ^d   White, E Lucile ^c   Aubé, Jeffrey ^a   Jonsson, Colleen B ^b   Chung, Donghoon ^b   Golden, Jennifer E ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Louisville School of Medicine   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ETHYLPIPERAZIN 1 YL) 6 NITRO 3 PHENYLQUINAZOLIN 4(3H) ONE; 2 [(1 ETHYL 4 METHYLPIPERAZIN 2 YLIDENE)AMINO] 5 NITRO N PHENYLBENZAMIDE; 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] 5 NITRO N (THIOPHEN 3 YL)BENZAMIDE; 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] 5 NITRO N PHENYLBENZAMIDE; 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] N (2 FLUOROPHENYL) 5 NITROBENZAMIDE; 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] N (3 FLUOROPHENYL) 5 NITROBENZAMIDE; 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] N (4 FLUOROPHENYL) 5 NITROBENZAMIDE; 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] N (4 METHOXYPHENYL) 5 NITROBENZAMIDE; 2 [(4 ETHYLPIPERAZIN 1 YL)METHYL] 3 (2 FLUOROPHENYL) 6 NITROQUINAZOLIN 4(3H) ONE; 2 [(4 ETHYLPIPERAZIN 1 YL)METHYL] 3 (3 FLUOROPHENYL) 6 NITROQUINAZOLIN 4(3H) ONE; 2 [(4 ETHYLPIPERAZIN 1 YL)METHYL] 3 (4 FLUOROPHENYL) 6 NITROQUINAZOLIN 4(3H) ONE; 2 [(4 ETHYLPIPERAZIN 1 YL)METHYL] 4 OXO 3 PHENYL 3,4 DIHYDROQUINAZOLINE 6 CARBONITRILE; 2 [(4 ETHYLPIPERAZIN 1 YL)METHYL] 6 NITRO 3 PHENYLQUINAZOLIN 4(3H) ONE; 2 [[METHYL[3-(METHYLAMINO)PROPYL]AMINO]METHYL] 6 NITRO 3 PHENYLQUINAZOLIN 4(3H) ONE, 2,2,2 TRIFLUOROACETIC SALT; 3 (2 FLUOROPHENYL) 2 [(4 METHYLPIPERAZIN 1 YL)METHYL] 6 NITROQUINAZOLIN 4(3H) ONE; 3 (2 FLUOROPHENYL) 6 NITRO 2 (PIPERAZIN 1 YLMETHYL) QUINAZOLIN 4(3H) ONE; 3 (4 METHOXYPHENYL) 6 NITRO 2 (PIPERAZIN 1 YLMETHYL)QUINAZOLIN 4(3H) ONE; 4 CHLORO 5 CYANO 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] N PHENYLBENZAMIDE; 5 CYANO 2 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] N PHENYLBENZAMIDE; 6 NITRO 2 (PIPERAZIN 1 YLMETHYL) 3 (THIOPHEN 3 YL) QUINAZOLIN 4(3H) ONE; 6 NITRO 3 PHENYL 2 (PIPERAZIN 1 YLMETHYL)QUINAZOLIN 4(3H) ONE; 6 NITRO 3 PHENYL 2 (PIPERIDIN 4 YL)QUINAZOLIN 4(3H) ONE; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; LIVE VACCINE; METHYL 4 [(1,4 DIMETHYLPIPERAZIN 2 YLIDENE)AMINO] 3 (PHENYLCARBAMOYL)BENZOATE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN; 2-((1,4-DIMETHYLPIPERAZIN-2-YLIDENE)AMINO)-5-NITRO-N-PHENYLBENZAMIDE; FUSED HETEROCYCLIC RINGS; MOLECULAR LIBRARY; QUINAZOLINONE DERIVATIVE;

ALPHAVIRUS INFECTION; AMIDATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BRAIN TISSUE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; EC50; HYDROGEN BOND; IN VITRO STUDY; LIVER HOMOGENATE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PLASMA PROTEIN BINDING; PROTECTION; PROTON NUCLEAR MAGNETIC RESONANCE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; C3H MOUSE; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; DRUG EVALUATION, PRECLINICAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HETEROCYCLIC COMPOUNDS, 2-RING; MICE, INBRED C3H; MICE, INBRED C57BL; PIPERAZINES; QUINAZOLINONES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84908388870     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501203v     Document Type: Article

References (37)

1. Johnston, R. E.; Peters, C. J. Alphaviruses. In Fields Virology, 3 rd ed.; Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., Straus, S. E., Eds.; Lippincott-Raven: Philadelphia, PA, 1996; pp 858-898.
2. Calisher, C. H. Medically important arboviruses of the United States and Canada Clin. Microbiol. Rev. 1994, 7, 89-116
3. Schmaljohn, A. L.; McClain, D. Alphaviruses (togaviridae) and flaviviruses (flaviviridae). In Medical Microbiology, 4 th ed.; Baron, S., Ed.; The University of Texas Medical Branch: Galveston, TX, 1996; http://www.ncbi.nlm.nih.gov/books/NBK7633/.
4. Nagata, L. P.; Wong, J. P.; Hu, W.-g.; Wu, J. Q. Vaccines and therapeutics for the encephalitic alphaviruses Future Virol. 2013, 8, 661-674
5. Gubler, D. J. The global emergence/resurgence of arboviral diseases as public health problems Arch. Med. Res. 2002, 33, 330-342
6. Sidwell, R. W.; Smee, D. F. Viruses of the bunya-and togaviridae families: potential as bioterrorism agents and means of control Antiviral Res. 2003, 57, 101-111
7. Peng, W.; Peltier, D. C.; Larsen, M. J.; Kirchhoff, P. D.; Larsen, S. D.; Neubig, R. R.; Miller, D. J. Identification of thieno[3,2- b ]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses J. Infect. Dis. 2009, 199, 950-957
8. Smith, J. F.; Davis, K.; Hart, M. K.; Ludwig, G. M.; McClain, D. J.; Parker, M. D. Viral encephalitides. In Medical Aspects of Chemical and Biological Warfare; Sidwell, R. V.; Takafuji, E. T.; Franz, D. R., Eds.; Borden Institute: Washington, DC, 1997; pp 561-589; http://www.cs.amedd.army.mil/borden/Portlet.aspx?ID=bddf382f-3ca0-44ba-bd67-fdc48bfa03de.
9. Weaver, S. C.; Barrett, A. D. Transmission cycles, host range, evolution and emergence of arboviral disease Nat. Rev. Microbiol. 2004, 2, 789-801
10. Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis and Venezuelan Equine Encephalomyelitis. Iowa State University, College of Veterinary Medicine: Ames, IA, 2008; pp 1-9; http://www.cfsph.iastate.edu/Factsheets/pdfs/easter-wester-venezuelan-equine-encephalomyelitis.pdf.
11. Zacks, M. A.; Paessler, S. Encephalitic alphaviruses Vet. Microbiol. 2010, 140, 281-286
12. Atasheva, S.; Garmashova, N.; Frolov, I.; Frolova, E. Venezuelan equine encephalitis virus capsid protein inhibits nuclear import in mammalian but not in mosquito cells J. Virol. 2008, 82, 4028-4041
13. Ehrenkrantz, N. J.; Ventura, A. K. Venezuelan equine encephalitis virus infection in man Annu. Rev. Med. 1974, 25, 9-14
14. McKinney, R. W.; Berge, T. O.; Sawyer, W. D.; Tigertt, W. D.; D, C. Use of an attenuated strain of Venezuelan equine encephalomyelitis virus for immunization in man Am. J. Trop. Med. Hyg. 1963, 12, 597-603
15. Cole, F. E.; May, S. W.; Eddy, G. A. Inactivated Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus Appl. Microbiol. 1974, 27, 150-153
16. McKinney, R. W. I nactivated and live VEE vaccines: a review. Venezuelan Encephalitis, Proceedings of the Workshop Symposium on Venezuelan Equine Encephalitis; Pan American Sanitary Bureau, Publication 243; Pan American Health Organization: Washington, DC, 1972; pp 369-389.
17. Edelman, R.; Ascher, M. S.; Oster, C. N.; Ramsurg, H. H.; Cole, F. E.; Eddy, G. A. Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C84) J. Infect. Dis. 1979, 140, 708-715
18. Davis, N. L.; Brown, K. W.; Greenwald, G. F.; Zajac, A. J.; Zacny, V. L.; Smith, J. F.; Johnston, R. E. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1 Virology 1995, 212, 102-110
19. Holley, H.; Fine, D.; Terpening, S.; Mallory, R.; Main, C.; Snow, D.; Helber, S. Safety of an Attenuated Venezuelan Equine Encephalitis Virus (VEEV) Vaccine in Humans. Presented at the 48th Annual ICAAC/IDSA Meeting, Washington, DC, October 25, 2008.
20. Julander, J. G.; Bowen, R. A.; Rao, J. R.; Day, C.; Shafer, K.; Smee, D. F.; Morrey, J. D.; Chu, C. K. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine Antiviral Res. 2008, 80, 309-315
21. Markland, W.; McQuaid, T. J.; Jain, J.; Kwong, A. D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon Antimicrob. Agents Chemother. 2000, 44, 859-866
22. Selvam, P.; Vijayalakshimi, P.; Smee, D. F.; Gowen, B. B.; Julander, J. G.; Day, C. W.; Barnard, D. L. Novel 3-sulphonamido-quinazolin-4(3 H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses Antiviral Chem. Chemother. 2007, 18, 301-305
23. Kehn-Hall, K.; Narayanan, A.; Lundberg, L.; Sampey, G.; Pinkham, C.; Guendel, I.; Van Duyne, R.; Senina, S.; Schultz, K. L.; Stavale, E.; Aman, M. J.; Bailey, C.; Kashanchi, F. Modulation of GSK-3β activity in Venezuelan equine encephalitis virus infection PLoS One 2012, 7, e34761
24. Molecular Libraries Program. https://mli.nih.gov/mli/mlpcn/.
25. Chung, D.-H.; Schroeder, C. E.; Sotsky, J.; Yao, T.; Roy, S.; Smith, R. A.; Tower, N. A.; Noah, J. W.; McKellip, S.; Sosa, M.; Rasmussen, L.; White, E. L.; Aubé, J.; Golden, J. E. ML336: Development of quinazolinone-based inhibitors against Venezuelan equine encephalitis virus (VEEV). In Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information: Bethesda, MD, 2012.
26. Chung, D.-H.; Jonsson, C. B.; Tower, N. A.; Chu, Y.-K.; Sahin, E.; Golden, J. E.; Noah, J. W.; Schroeder, C. E.; Sotsky, J. B.; Sosa, M. I.; Cramer, D. E.; McKellip, S. N.; Rasmussen, L.; White, E. L.; Schmaljohn, C. S.; Julander, J. G.; Smith, J. M.; Filone, C. M.; Connor, J. H.; Sakurai, Y.; Davey, R. A. Discovery of a novel compound with anti-Venezuelan equine encephalitis virus activity that targets the nonstructural protein 2 PLoS Pathog. 2014, 10, e1004213
27. Griffin, D. E. Viral encephalomyelitis PLoS Pathog. 2011, 7, e1002004
28. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs NeuroRx 2005, 2, 541-553
29. Ghose, A. K.; Herbertz, T.; Hudkins, R. L.; Dorsey, B. D.; Mallamo, J. P. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery ACS Chem. Neurosci. 2012, 3, 50-68
30. Stockwell, B. Compounds and compositions that cause non-apoptotic cell death and uses thereof. WO 2009108384A2, 2009.
31. Acharyulu, P. V. R.; Dubey, P. K.; Reddy, P. V. V. P.; Suresh, T. Synthesis of novel new 2-(2-(4-((3,4-dihydro-4-oxo-3-aryl quinazolin-2-yl)methyl)piperazin-1-yl)acetoyloxy)-2-phenyl acetic acid esters Synth. Commun. 2009, 39, 3217-3231
32. Schroeder, C. E.; Yao, T.; Neuenswander, S. A.; Aubé, J.; Golden, J. E. Unpublished results.
33. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
34. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
35. McAnally, D.; Vicchiarelli, M.; Siddiquee, K.; Smith, L. H. In vivo rapid assessment of compound exposure (RACE) for profiling the pharmacokinetics of novel chemical probes Curr. Protoc. Chem. Biol. 2012, 4, 299-309
36. Rich, J. T.; Neely, J. G.; Paniello, R. C.; Voelker, C. C. J.; Nussenbaum, B.; Wang, E. W. A practical guide to understanding Kaplan-Meier curves Otolaryngol. Head Neck Surg. 2010, 143, 331-336
37. Shin, G.; Yost, S. A.; Miller, M. T.; Elrod, E. J.; Grakoui, A.; Marcotrigiano, J. Structural and functional insights into alphavirus polyprotein processing and pathogenesis Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 16534-16539